Table 6.
Author | Year | Study design | Health status | Number of participants | Mean age (years) | Sex (% F) | BMI (kg/m2) | Duration (days) | Wash out (days) | Supplement | Dose (mg/day) | Flow mediated dilation (∆ %) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control baseline/final (mean ± SD) | Supplement baseline/final (mean ± SD) | ||||||||||||
Lekakis et al. | 2005 | P | CHD |
Control: 15 Supp: 15 |
61.0 | M | 28.0 | 0 | NA | GE | 600 | 2.75 ± 1.85/2.64 ± 1.8 | 2.6 ± 1.5/4.52 ± 1.34 |
Marques et al. | 2018 | X | ED |
Control: 24 Supp: 24 |
54 | 58 | 30 | 0 | 7 | RSV | 300 | 4.1 ± 0.9/2.64 ± 1.8 | 2.6 ± 1.5/4.52 ± 1.34 |
Mellen et al. | 2010 | X | Pre-MS |
Control: 50 Supp: 50 |
52.1 | 50 | 29.8 | 28 | 28 | RSV | 1300 | 5.27 ± 0.42/5.18 ± 0.38 | 5.22 ± 0.32/4.57 ± 0.32 |
Van Mierlo et al. | 2010a | X | Healthy |
Control: 35 Supp: 35 |
31.4 | M | 23.2 | 14 | 7 | GE | 1405 | 5.6 ± 3.6/3.9 ± 2.96 | 5.6 ± 3.6/3.5 ± 5.66 |
2010b | X | Healthy |
Control: 35 Supp: 35 |
31.4 | M | 23.2 | 14 | 7 | GSE | 2547 | 5.6 ± 3.6/3.9 ± 2.96 | 5.6 ± 3.6/4.1 ± 5.66 | |
Wong et al. | 2011a | X | O |
Control: NA Supp: 18 |
55 | 27.8 | 28.7 | 0 | 7 | RSV | 30 | NA | 4.06 ± 3.39/6.56 ± 4.76 |
2011b | X | O |
Control: NA Supp: 18 |
55 | 27.8 | 28.7 | 0 | 7 | RSV | 90 | NA | 4.06 ± 3.39/6.45 ± 3.61 | |
2011c | X | O |
Control: NA Supp: 18 |
55 | 27.8 | 28.7 | 0 | 7 | RSV | 270 | NA | 4.06 ± 3.39/7.73 ± 6.34 | |
Wong et al. | 2013 | X | O |
Control: 28 Supp: 28 |
61 | 57.1 | 33.3 | 42 | 0 | RSV | 75 | 5.83 ± 0.68/5.48 ± 0.69 | 7.21 ± 0.51/7.42 ± 0.62 |
Xue et al. | 2016 | X | O |
Control: 29 Supp: 29 |
45 | 72.4 | 34.1 | 56 | 42 | RSV + HESP | 210 | 0.247 ± 0.327/0.267 ± 0.312 | 0.207 ± 0.195/0.163 ± 0.195 |
Xue et al., 2016 results are change in diameter not percentage change
X cross-over, P parallel arm, CHD coronary heart disease, MS metabolic syndrome, ED endothelial dysfunction, O obese, RSV resveratrol, GE grape extract, GSE grape seed extract, GADF grape antioxidant dietary fibre, HESP hesperetin